Dianthus Therapeutics
DNTH
102 hedge funds and large institutions have $729M invested in Dianthus Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 29 increasing their positions, 40 reducing their positions, and 14 closing their positions.
369% more call options, than puts
Call options by funds: $2.68M | Put options by funds: $572K
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
6% more capital invested
Capital invested by funds: $685M → $729M (+$43.1M)
4.22% more ownership
Funds ownership: 117.38% → 121.6% (+4.2%)
4% more funds holding
Funds holding: 98 → 102 (+4)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
28% less repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$28.1M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$14.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.33M |
| 4 |
Goldman Sachs
New York
|
+$5.46M |
| 5 |
Millennium Management
New York
|
+$3.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$14M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$13.7M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$6.81M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$4.99M |
| 5 |
BlackRock
New York
|
-$4.82M |
DNTH Hedge Fund Activity: Q2 2025 in Review
102 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2025, worth a combined $729M — up 6.3% from $685M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new DNTH positions and 14 closed out — a net gain of 4 holders — while 29 added to existing stakes and 40 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $28.1M. The largest seller was VR Adviser, cutting an estimated $14M.
- 102 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2025, up from 98 in Q1 2025.
- Funds reported $729M of Dianthus Therapeutics stock for Q2 2025, up 6.3% quarter-over-quarter.
- 18 funds opened new Dianthus Therapeutics positions in Q2 2025 and 14 closed out, a net change of +4 holders.
- The largest Dianthus Therapeutics buyer in Q2 2025 was Vestal Point Capital, an estimated $28.1M added.
- The largest Dianthus Therapeutics seller in Q2 2025 was VR Adviser, an estimated $14M sold.
Based on aggregated 13F filings for Q2 2025.